Survival in cervical cancer IIb-IVA subjected to postchemo-radiotherapy surgery in Ecuador.

José Luís Reyes Sociedad de Lucha Contra El Cancer, Guayaquil, Guayas, Ecuador info_outline José Luís Reyes, Walter Morquecho, Mario Argüello, Fausto Emiliano Pulla, Mayra Santacruz, Elizabeth Graciela Veliz, Carlos Jose Alarcon, Jenniffer Stefania Plaza, Nery Abdon Rivadeneira

Authors José Luís Reyes Sociedad de Lucha Contra El Cancer, Guayaquil, Guayas, Ecuador info_outline José Luís Reyes, Walter Morquecho, Mario Argüello, Fausto Emiliano Pulla, Mayra Santacruz, Elizabeth Graciela Veliz, Carlos Jose Alarcon, Jenniffer Stefania Plaza, Nery Abdon Rivadeneira Organizations Sociedad de Lucha Contra El Cancer, Guayaquil, Guayas, Ecuador, Sociedad de Lucha Contra El Cáncer, SOLCA - Guayaquil, Guayaquil, Ecuador Abstract Disclosures Research Funding No funding sources reported Background: Cervical cancer (CC) is one of the leading causes of cancer death in the world. The objective of the present study is to determine the overall survival (OS), survival by age group, and histological type in patients with locally advanced CC undergoing salvage surgery after chemo-radiotherapy (CTx-RTx). Methods: A retrospective observational analytical study was carried out on patients with locally advanced CC with stages IIB-IVA who received CTx-RTx treatment from January 2010 to December 2014 with follow-up until August 2023 in SOLCA-Guayaquil. The SPSSv29 statistical program was used to analyze survival curves with the Kaplan-Meier estimator and Log-Rank test. Results: Of a total of 1909 patients, 1581 were excluded because they did not meet eligibility criteria. 328 received CTx-RTx, and 23 underwent rescue surgery. The average survival result is 107 months (m). In survival by histological type, 11 patients presented squamous cell carcinoma (SCC) and 12 adenocarcinoma (AC), with the mean survival for SCC 111 months and for AC 94 months, however in the Log-Rank statistical test (p: 0.672) was not significant, which is why it is estimated that survival is similar in the two histological types (graph 2). In the calculation of survival by age in m (every ten years), in the first group of 30-39 years, it is 98.1 m, 40-49 years 118.8 m, 50-59 years 98.6 m, 60 or more years, it is 56 m; however, in the Log-Rank statistical test (p = 0.317), it is not significant by age group. Conclusions: Of the 23 patients with a mean age of 48 years and a follow-up of 168 months, 13 (56%) are alive. Regarding survival by histological type and age group, there was no significant difference in survival with these results. Means and medians for survival time. Age Groups* Mean a Median Estimate Sth. Error 95% Confidence Interval Estimate Sth. Error 95% Confidence Interval Lower Bound Upper Bound Lower Bound Upper Bound 30 a 39 98,167 16,850 65,141 131,192 87,000 . . . 40 a 49 118,857 19,954 79,746 157,968 . . . . 50 a 59 98,667 12,929 73,327 124,007 . . . . 60 or more 56,000 14,418 27,741 84,259 34,000 10,000 14,400 53,600 Overall 106,696 11,004 85,128 128,263 . . . . a Estimation is limited to the largest survival time if it is censored. *Age in years.